Skip to main content
Equibles
CRMD logo

CRMD · CorMedix Inc.

Track CRMD — free

Use CRMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CRMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$7.18 -0.01 (-0.14%)
Russell 2000 member Rebalance outlook locked
Market Cap
$611.47M
Shares
77.94M
Volume · Oct 5 500.32K Avg daily vol (3M) 1.06M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$7.19 Open$7.45 Day$7.17–7.45 52W close$6.25–12.73 Avg vol 30d905K Short int16.2M · 20.8% float · 18.5d Short vol65% Last earningsAug 13, 2026 DataJan 2020–Oct 2026 Filing10-Q · Aug 13

Up next

Next earnings call
Nov 15, 2026 Est · unconfirmed · in 6 wks
Latest filing: 10-Q
filed Aug 13, 2026
Q1 2026 earnings call transcript
call held May 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$462.25M
Trailing 12 months
Net income (TTM)
$187.17M
Trailing 12 months
Revenue growth YoY
+156.5%
Year over year
Operating margin
47.0%
Trailing 12 months
P / E (TTM)
3.3
Trailing earnings · reciprocal yield 30.3%
FCF yield
41.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$256.69M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+28.6%
Year over year · more shares
Price change (1Y)
-34.9%
Trailing year
Short interest
20.8%
Latest settlement · 18.5 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −10%
below
Price vs 50-day avg −9%
below
RSI (14) 32
neutral
MACD trend Negative
52-week position 15%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −15%
trailing
6-month return −2%
trailing
YTD return −38%
this year
Relative strength −14%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $8 › 200d $8 — 200d above 50d
Institutional flow Accumulating
+2% holders QoQ · +27 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
20.79% of float · ▲ +1.1% MoM · 18.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
196 holders — near 3-yr high, broad support
Squeeze score 77
high risk · 0–100
Fundamentals
Excellent
Revenue growth +617%
Y/Y
Gross margin 88%
contracting
EPS growth +780%
Y/Y
Free cash flow $172.8M
Buyback $75.0M
authorized
Quant / Vol
risk profile
Very High
Volatility 61%
annualized · 1-yr
Max drawdown −51%
past year
ATR 3.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 13, 2026
Consolidated revenue · full-year 2026 Initiated $325M – $345M
prior FY $311.71M midpoint +7.5% Y/Y
Adjusted EBITDA · full-year 2026 Non-GAAP Initiated $125M – $140M
Cash OpEx · full-year 2026 Initiated $145M – $155M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−10% Bearish
Price vs 50-day avg
−9% Bearish
RSI (14)
32 Neutral
MACD trend
Negative Bearish
52-week position
15% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $8 › 200d $8 — 200d above 50d
Institutional flow Accumulating
+2% holders QoQ · +27 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
20.79% of float · ▲ +1.1% MoM · 18.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
196 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6 Now $7 · 15% Range high $13
vs 200-day avg -10% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Melinta portfolio net revenue $35.8M the second quarter of 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CRMD
CorMedix Inc.
this stock
$611.47M -38.2% +617.0% — 20.8%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
196
% held
58.9%
Net QoQ
+1.2M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
146
View
Short & Settlement
Short Interest Rising
Shares short
16.2M
Days to cover
18.5d
Change
+170.2K sh
View
Short Volume
Short vol %
65%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
1.0K
Value
$8.5K
As of
Sep 10, 2026
View
Off-Exchange
Off-exchange %
38.7%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$311.7M
Net income (FY)
$163.1M
EPS diluted
$2.04
View
Buybacks
Authorized
$75.0M
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 9, 2026
This year
16
View
Proposed Sales
Value
$68.5K
Shares
10.0K
Filed
Jan 21, 2026
View
Earnings & Events
Webcasts
Last webcast
Sep 9, 2026
View

Performance

5D 20D 120D MTD YTD
CRMD -8.4% -15.1% -1.8% -6.6% -38.2%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY -8.2% -14.7% -14.0% -7.5% -51.0%

Capital returns

Buyback program · as of Feb 2, 2026
Authorized
$75.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1410098 CUSIP 21900C308 13F (30d) 3 filings 3 filers Visit website Investor relations